Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients

Share :
Published: 28 Dec 2023
Views: 76
Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Dr Oleg Gluz speaks to ecancer about the multicenter ADAPTcycle trial. This study investigated the impact of age and ovarian function suppression (OFS) on endocrine response to short-preoperative endocrine therapy (ET).

ADAPTcycle confirms ADAPT ET-response rates in patients receiving tamoxifen or aromatase inhibitors; adding OFS improves ET-response, irrespective of recurrence score. Endocrine therapy response measurement adds value to therapy decisions, particularly in 50-year-old or above patients.

The study found that optimal preoperative ET, especially in premenopausal patients, might even enable sparing chemotherapy in additional patients.